The association of body mass index and prostate-specific antigen in a population-based study.


Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma.

The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute.

The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age.

Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.

  • Baillargeon J
  • Basler J
  • Bradshaw P
  • Hernandez J
  • Higgins B
  • Kristal AR
  • Lynch S
  • Pollock BH
  • Rozanski T
  • Thompson I
  • Troyer D
PubMed ID
Appears In
Cancer, 2005, 103 (5)